Anti-CD37 targeted immunotherapy of B-Cell malignancies

• Published in: Biotechnology letters 2018-12, Vol.40 (11-12), p.1459-1466
• Main Authors: Payandeh, Zahra, Noori, Effat, Khalesi, Bahman, Mard-Soltani, Maysam, Abdolalizadeh, Jalal, Khalili, Saeed
• Format: Article
• Language: English
• Subjects: Antigens, Neoplasm; Applied Microbiology; Biochemistry; Biomedical and Life Sciences; Biotechnology; Chronic lymphocytic leukemia; Clinical trials; Domains; Humans; Immunoglobulin G - therapeutic use; Immunotherapy; Leukemia, B-Cell - therapy; Life Sciences; Lymphocytes B; Lymphoma, Non-Hodgkin - therapy; Medical research; Microbiology; Monoclonal antibodies; Patients; Proteins; Recombinant Fusion Proteins - therapeutic use; Review; Tetraspanins - antagonists & inhibitors; Toxicity; Transmembrane domains
• ISSN: 0141-5492; 1573-6776
• DOI: 10.1007/s10529-018-2612-6

CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained.